Kallikrein-8 inhibition attenuates Alzheimer’s pathology in mice

Herring, Arne; Münster, Yvonne; Akkaya, Tamer; Moghaddam, Sahar; Deinsberger, Katharina; Meyer, Jakob; Zahel, Julia; Sanchez-Mendoza, Eduardo; Wang, Yachao; Hermann, Dirk M. LSF; Arzberger, Thomas; Teuber-Hanselmann, Sarah; Keyvani, Kathy LSF

Introduction

Memory loss and increased anxiety are clinical hallmarks of Alzheimer's disease (AD). Kallikrein-8 is a protease implicated in memory acquisition and anxiety, and its mRNA is known to be up-regulated in AD-affected human hippocampus. Therefore, an involvement of Kallikrein-8 in Alzheimer's pathogenesis is conceivable but remains to be proved.

Methods

We determined the cerebral expression of Kallikrein-8 mRNA and protein during the course of AD in patients and in transgenic mice and tested the impact of Kallikrein-8 inhibition on AD-related pathology in mice and in primary glial cells.

Results

Kallikrein-8 mRNA and protein were up-regulated in both species at incipient stages of AD. Kallikrein-8 inhibition impeded amyloidogenic amyloid-precursor-protein processing, facilitated amyloid β (Aβ) clearance across the blood-brain-barrier, boosted autophagy, rAβ load and tau pathology, enhanced neuroplasticity, reversed molecular signatures of anxiety, and ultimately improved memory and reduced fear.

Discussion

Kallikrein-8 is a promising new therapeutic target against AD.

Share and cite

Citation style:

Herring, Arne / Münster, Yvonne / Akkaya, Tamer / et al: Kallikrein-8 inhibition attenuates Alzheimer’s pathology in mice. 2016.

Could not load citation form. Default citation form is displayed.

Rights

Export